JPMorgan reiterates Overweight rating on Protagonist Therapeutics stock
Post Content
Business & Finance
Stay informed with expert takes on business strategy, investing, entrepreneurship, and global markets. CurioAtlas brings you articles that guide smarter decisions in finance and business growth.
JPMorgan reiterates Overweight rating on Vera Therapeutics stock
Post Content
JPMorgan maintains Overweight rating on ServiceNow stock amid mixed partner feedback
Post Content
JPMorgan reports rotation from US to international equity ETFs
Post Content
Baker Hughes stock price target raised to $60 by JPMorgan on power systems growth
Post Content
IonQ stock to acquire SkyWater Technology for $1.8 billion
Post Content
Gresham House Asset Management reduces stake in Property Franchise Group
Post Content
Wall Street veteran who called the dot-com bust sees a bigger bubble in Magnificent 7
Richard Bernstein says investors are ignoring a whole bunch of high-earning companies for the sake of a few tech giants.
HCA Healthcare beats Q4 earnings, stock falls on revenue miss
Post Content
I Called Micron’s Surge a Few Months Ago. Here’s How High I See the AI Stock Going This Year.
Post Content